3D Investment Partners Sells 640K MediciNova Shares, Adds TRS Exposure
MNOV sits 64% above its 52-week low of $1.168 on elevated volume (1.9× avg).
Summary
3D Investment Partners sold 640,000 MediciNova shares at ~US$2.7 each and added total return swap exposure on 456,637 notional shares, keeping its stake at 9.9%.
Key Events · Ownership and Investor Activity · MNOV
-
640K Share Sale via ADS
3D Investment Partners sold 640,000 shares at JPY425 (~US$2.7) per share on September 25, 2026, in a private accelerated share disposal to a third-party financial institution.
-
New Total Return Swaps
The fund entered cash-settled total return swaps on 456,637 notional shares (~0.9% of outstanding), retaining economic exposure without voting or dispositive power.
-
Ownership Remains at 9.9%
Post-transaction, 3D Investment Partners beneficially owns 4,862,047 shares, representing 9.9% of MediciNova's 49,221,246 outstanding shares.
-
Observer Right Lapsed
The fund's Observer Appointment Right under the Shareholder Rights Agreement lapsed as of 2024, ending its board observation role.
Analysis · MNOV · Life Sciences
3D Investment Partners, MediciNova's largest institutional holder at 9.9%, sold 640,000 shares via an accelerated share disposal at JPY425 (~US$2.7) per share on September 25, 2026. The sale reduces its direct stake while the fund simultaneously entered cash-settled total return swaps on 456,637 notional shares, maintaining economic exposure without voting rights. This comes just days after positive Phase 2 NAFLD data and completion of the COMBAT-ALS trial, suggesting the fund is monetizing part of its position while retaining upside via derivatives.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MNOV was trading at $1.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $94.5M. The 52-week trading range was $1.17 to $3.90. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.